These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30216494)

  • 41. Biologic treatments for elderly patients with psoriasis.
    Momose M; Asahina A; Hayashi M; Yanaba K; Umezawa Y; Nakagawa H
    J Dermatol; 2017 Sep; 44(9):1020-1023. PubMed ID: 28439956
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
    JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence of Phototherapy in the Age of Biologics.
    Calzavara-Pinton P; Zanca A; Arisi M; Rossi MT; Zane C; Venturini M; Ortel B
    Dermatology; 2018; 234(5-6):166-172. PubMed ID: 30205372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis.
    Stiff KM; Glines KR; Porter CL; Cline A; Feldman SR
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1209-1218. PubMed ID: 30449211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Why Biologic Therapies Sometimes Lose Efficacy.
    Strober BE
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S78-80. PubMed ID: 27525443
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Possibilities and limits for treating psoriasis with biologics. Case reports].
    Süss A; Colsman A; Simon JC; Sticherling M
    Hautarzt; 2009 Jan; 60(1):51-6. PubMed ID: 18712323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Psoriasis & psoriatic therapies.
    Cantrell W
    Nurse Pract; 2017 Jul; 42(7):35-39. PubMed ID: 28622256
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum YKL-40 as a potential biomarker of inflammation in psoriasis.
    Baran A; Myśliwiec H; Szterling-Jaworowska M; Kiluk P; Świderska M; Flisiak I
    J Dermatolog Treat; 2018 Feb; 29(1):19-23. PubMed ID: 28498006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER).
    Lambert J; Ghislain PD; Lambert J; Cauwe B; Van den Enden M
    J Dermatolog Treat; 2017 Aug; 28(5):394-400. PubMed ID: 27791446
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Therapeutic strategies against psoriasis. Skin to hide -- and how do you free your patients from it].
    Stiefelhagen P
    MMW Fortschr Med; 2007 Sep; 149(35-36):12-4. PubMed ID: 17944277
    [No Abstract]   [Full Text] [Related]  

  • 51. Serum irisin levels in patients with psoriasis.
    Baran A; Myśliwiec H; Kiluk P; Świderska M; Flisiak I
    J Dermatolog Treat; 2017 Jun; 28(4):304-308. PubMed ID: 27786588
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rational for statin use in psoriatic patients.
    Mosiewicz J; Pietrzak A; Chodorowska G; Trojnar M; Szepietowski J; Reich K; Rizzo M
    Arch Dermatol Res; 2013 Aug; 305(6):467-72. PubMed ID: 23754638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Geographic Variations in Biologic Therapy and Disease Characteristics: A Pilot-Study in the Corrona Psoriasis Registry.
    Enos CW; O'Connell KA; Harrison RW; McLean RR; Dude B; Van Voorhees AS
    J Drugs Dermatol; 2020 Nov; 19(11):1119-1122. PubMed ID: 33196741
    [No Abstract]   [Full Text] [Related]  

  • 54. Marked decrease in serum squamous cell carcinoma antigen level after antitumor necrosis factor alpha therapy in six cases of severe psoriasis.
    Iriki H; Tanese K; Furuichi Y; Takeshita K; Saito M
    Int J Dermatol; 2016 Jun; 55(6):e364-6. PubMed ID: 26696364
    [No Abstract]   [Full Text] [Related]  

  • 55. HLA-G 14-bp polymorphism: a possible marker of systemic treatment response in psoriasis vulgaris? Preliminary results of a retrospective study.
    Borghi A; Rizzo R; Corazza M; Bertoldi AM; Bortolotti D; Sturabotti G; Virgili A; Di Luca D
    Dermatol Ther; 2014; 27(5):284-9. PubMed ID: 24909182
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of biologic agents in pediatric psoriasis.
    Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
    J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection.
    Peccerillo F; Odorici G; Pellacani G; Conti A
    Dermatol Ther; 2018 Jul; 31(4):e12601. PubMed ID: 29633448
    [No Abstract]   [Full Text] [Related]  

  • 59. Expression of the psoriasis-associated antigen, Pso p27, is inhibited by cyclosporin A.
    Dalaker M; Jacobsen T; Lysvand H; Iversen OJ
    Acta Derm Venereol; 1999 Jul; 79(4):281-4. PubMed ID: 10429984
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels.
    Baran A; Świderska M; Myśliwiec H; Flisiak I
    J Dermatolog Treat; 2017 Mar; 28(2):136-140. PubMed ID: 27165470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.